Laboratory Investigation · 2017 · 207 citations · 50 references
Life SciencesImmunologyOncologyMolecular OncologyTumor ImmunologyTumor MicroenvironmentMelanocytic TumorsTumor AntigensTumor CharacterizationTumor ClassificationTumor MarkersTumor-associated AntigensMelanocytic Tumor Molecular PathologyMelanoma BiomarkersMelanoma ClassificationMelanoma-associated AntigensProgrammed Death-ligand 1 Biomarker
50
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17